We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AYTU BioPharma Inc | NASDAQ:AYTU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0084 | -0.27% | 3.1216 | 2.90 | 3.19 | 3.15 | 3.08 | 3.15 | 16,802 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 1, 2016
Registrant’s Telephone Number, Including Area Code: (720) 437-6580
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.03. | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On June 1, 2106, we filed a certificate of amendment with the Delaware Secretary of State for the purpose of amending our certificate of incorporation to decrease the number of shares of common stock the Company has the authority to issue from 300,000,000 shares to 100,000,000 shares. This amendment was described in our definitive proxy statement for our annual meeting of shareholders held on May 24, 2016 and was approved by our shareholders at the annual meeting. We reported the voting results from the annual meeting in a Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 25, 2016.
Item 9.01. | Financial Statements and Exhibits |
(d) | Exhibits. |
Exhibit No. |
Description of Exhibit
|
3.1 | Certificate of Amendment of Certificate of Incorporation of Aytu Bioscience, Inc., effective June 1, 2016. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 2, 2016 | AYTU BIOSCIENCE, INC. |
/s/ Gregory A. Gould | |
Name: Gregory A. Gould | |
Title: Chief Financial Officer |
1 Year AYTU BioPharma Chart |
1 Month AYTU BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions